Unimoc

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unimoc

Property Description
Active Ingredients Amoxicillin and Clavulanate Potassium
Pharmacological Class beta-Lactam/beta-Lactamase Inhibitor Antibiotic
Forms Tablet, Chewable tablet, Powder for Oral Suspension, Injection
Common Use Eliminating bacterial infections
Origin Semisynthetic

What Type of Medicine is Unimoc?

Unimoc is a brand name for the pharmaceutical product known internationally as Co-amoxiclav, which uses the official International Nonproprietary Name (INN) Amoxicillin and Clavulanate Potassium. This is a prescription-only, fixed-dosage combination product classified as an antibacterial agent. Specifically, it belongs to the beta-Lactam/beta-Lactamase Inhibitor pharmacological class. This dual composition is engineered to broaden the spectrum of bacterial susceptibility, ensuring that the primary antibiotic component remains effective.

The Composition and Function of Co-amoxiclav

The medicine is composed of the semisynthetic antibiotic Amoxicillin and the beta-lactamase inhibitor Clavulanic Acid (supplied as its potassium salt). Amoxicillin provides the bactericidal effect by disrupting the structural components of the bacterial cell wall. Clavulanic Acid works primarily as a protective agent for the antibiotic. The presence of Clavulanic Acid extends the therapeutic scope of Amoxicillin to cover many organisms that would otherwise be resistant. Unimoc is available for the oral route in common dosage forms such as tablets and a powder for oral suspension (liquid).

The General Purpose of this Antibacterial Agent

The general purpose of Unimoc is to provide a reliable, broad-spectrum solution for eliminating bacterial infections. Its two-part mechanism—the potent effect of Amoxicillin paired with the resistance-countering action of Clavulanic Acid—enables the medicine to effectively combat a wide range of bacterial pathogens. This makes it particularly valuable for typical use scenarios involving infections caused by beta-lactamase-producing strains.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Unimoc?

The safety profile of Unimoc (Amoxicillin and Clavulanate Potassium) is formally documented based on regulatory standards. Adverse reactions are classified by frequency and by the organ system affected, with the majority of reported effects primarily involving the gastrointestinal system and skin.

Frequency Classification of Adverse Reactions

Adverse reactions classified as Common (affecting up to 1 in 10 individuals) principally include Diarrhea, Nausea, and Vomiting. Nausea is noted in regulatory documents to be more frequently observed at higher oral doses.

Reactions classified as Uncommon (affecting up to 1 in 100 individuals) include Dizziness, Headache, Indigestion, and skin reactions such as Rash, Pruritus (itching), and Urticaria (hives). Asymptomatic increases in liver enzymes are also listed in this category.

Documented Serious Safety Concerns

Although classified as rare or very rare, the official safety profile includes potentially serious adverse reactions. These include Hepatitis and Cholestatic Jaundice (Hepatic Events), Antibiotic-associated colitis, and severe hypersensitivity events such as Anaphylaxis and Angioedema. Hypersensitivity reactions are generally noted to be more likely to occur at the start of treatment.

Safety Considerations for Specific Populations

Official labeling outlines specific restrictions. Unimoc is contraindicated in individuals with a previous history of product-related jaundice or hepatic dysfunction. Caution is specified for use in individuals with existing hepatic impairment, and dose adjustments are required for those with moderate or severe renal impairment. Hepatic events are noted to be more common in males and older adults and may have a delayed onset after treatment is stopped.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Unimoc (Amoxicillin and Clavulanate Potassium) is primarily associated with manifestations affecting the gastrointestinal, renal, and central nervous systems. Officially documented presentations include severe gastrointestinal symptoms such as persistent vomiting, diarrhea, and abdominal discomfort, which may lead to fluid and electrolyte imbalance.

A significant finding documented in regulatory labeling is amoxicillin crystalluria, where crystals form in the urine. This condition may present with oliguria (greatly decreased urine output) and holds the potential risk of acute renal injury. For patients with existing impaired renal function, the occurrence of severe central nervous system effects, particularly convulsions or seizures, is heightened following high-dose exposure.

Because of the potential for severe complications, official regulatory guidance mandates that individuals must seek immediate medical attention if an overdose is suspected or if any documented severe symptoms, such as a seizure or significantly decreased urination, occur. There is no specific antidote known for this medication. Treatment is officially defined as symptomatic and supportive. Supportive measures described in prescribing information include correction of fluid imbalance and the use of haemodialysis to effectively remove the active substances from the body.

Therapeutic Uses of Unimoc

What Unimoc Treats: Main Uses and Benefits

Unimoc is a prescription antibacterial agent commonly used to manage infections caused by susceptible bacteria and is applied across therapeutic domains involving heightened physiological activity. Its use is relevant for easing symptomatic discomfort across several key domains.

The medicine is commonly used across conditions characterized by periods of heightened symptoms, such as acute episodes of respiratory infections (including acute bacterial rhinosinusitis, acute otitis media, and community-acquired pneumonia), certain skin and soft tissue infections (like cellulitis), and specific urinary tract infections. This agent supports the management of symptoms that interfere with daily comfort, such as fever, localized pain, swelling, and difficulty breathing. Its use assists with maintaining functional stability and helps patients cope more steadily with difficult episodes by contributing to easing the overall symptom load.


Quick Fact: Relief for Inflammatory Symptoms

Unimoc is relevant in clinical settings that involve acute or sudden symptom patterns, particularly those related to inflammatory or irritative states in the lungs, sinuses, middle ear, and skin, and may be part of symptomatic management to help ease patient distress.

Eligibility and Restrictions for Use

Unimoc is an antibiotic medication containing amoxicillin and clavulanic acid, and its use is subject to specific medical criteria. It is prescribed for adults and children to treat various bacterial infections, including those affecting the ear, nose, throat, respiratory tract, urinary tract, and skin.

Contraindications (Who Cannot Use Unimoc)

Unimoc should not be used if a patient has a known allergy to amoxicillin, clavulanic acid, or any other penicillin antibiotic. Patients with a history of severe allergic reactions to other beta-lactam antibiotics, such as cephalosporins, should also avoid this medicine. Additionally, it is strictly contraindicated for individuals who have previously experienced liver problems or jaundice when taking Unimoc or similar amoxicillin/clavulanic acid combinations.


Special Patient Groups (Use with Caution)

Special consideration and careful medical consultation are essential for certain groups:

  • Pregnancy and Breastfeeding: Use during pregnancy is not recommended unless deemed essential by a physician. Women who are breastfeeding are advised against using Unimoc, as its components pass into breast milk and may cause diarrhea or fungal infections in the infant.
  • Existing Conditions: Caution is necessary for patients with severe kidney impairment (as dosage adjustments may be required) and those with a history of liver dysfunction.
  • Elderly Patients: Individuals over the age of 60 may require closer monitoring, particularly regarding liver and kidney function.

What should I know about interactions with other medicines?

Unimoc, which contains amoxicillin and clavulanic acid, may interact with several other medications. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are currently taking.

Medications Requiring Caution

Caution is advised when Unimoc is taken alongside the following types of medicines:

  • Oral Anticoagulants (Blood Thinners): Medicines like warfarin or acenocoumarol may have their effect enhanced, increasing the risk of bleeding. Regular monitoring of blood tests (such as PT-INR) is typically required.
  • Methotrexate: Used in the treatment of cancer or certain autoimmune disorders. Unimoc can potentially increase the side effects and toxicity of methotrexate by reducing its renal excretion.
  • Allopurinol or Probenecid: Used to treat gout. Combining these with Unimoc can increase the blood levels of amoxicillin.
  • Mycophenolate Mofetil: Used to prevent organ transplant rejection. Unimoc can reduce the amount of this drug in the body, potentially leading to reduced effectiveness.
  • Oral Contraceptives: Unimoc may decrease the effectiveness of hormonal birth control pills. Additional non-hormonal contraception methods (e.g., condoms) should be considered during treatment and for seven days after completing the course.

Mechanism of Action

Unimoc operates through a complementary, bactericidal mechanism involving two distinct active ingredients that target critical bacterial survival and defense pathways. The mechanistic consequence of this action is the destruction of the bacterial structure.


Irreversible Disruption of Cell Wall Assembly

The primary component, Amoxicillin, exerts its effect by binding to and permanently inhibiting Penicillin-Binding Proteins (PBPs), a class of bacterial enzymes responsible for building the structural cross-links in the peptidoglycan layer of the cell wall. This mechanism immediately halts the construction and repair of the cell wall, leading to the rapid destabilization and lysis (death) of the susceptible bacterial cell due to internal osmotic pressure.


Restoration of Activity Against Enzymatic Resistance

The second component, Clavulanate Potassium, operates to protect the primary mechanism. It acts as a suicide inhibitor against beta-lactamase enzymes, which are produced by resistant bacteria to chemically inactivate Amoxicillin. By permanently deactivating these defense enzymes, Clavulanate ensures the full concentration of Amoxicillin remains active and available to reach its PBP target. This synergy ensures that Amoxicillin's PBP-inhibitory mechanism is functional against beta-lactamase-expressing strains.

Dosage and Administration Information

The administration of Unimoc (Amoxicillin and Clavulanate Potassium) is governed by instructions detailing dosing, frequency, and specific handling requirements for its oral and intravenous formulations.

Official Dosing and Frequency

Oral therapy is typically prescribed using twice-daily (every 12 hours) or three-times-daily (every 8 hours) schedules. Adult dosing for immediate-release tablets ranges from 500 mg/125 mg to 875 mg/125 mg, based on the prescribed regimen. The course of treatment must not be extended beyond 14 days without re-evaluation. Pediatric dosing for patients weighing less than 40 kg is determined by weight-based calculations (mg/kg/day).

Administration Requirements

Requirement Instruction
Timing with Meals Oral forms should be taken at the start of a meal to enhance absorption of the clavulanate component and minimize potential gastrointestinal intolerance.
Formulation Handling Extended-release tablets must be swallowed whole; they are not intended to be crushed or chewed. Oral suspension powder requires reconstitution with water and must be shaken well prior to each dose.

Population-Specific Adjustments

Dose adjustments are required for patients with impaired renal function. Patients with a glomerular filtration rate (GFR) of 10 to 30 mL/min must receive a reduced dose every 12 hours, while those with GFR less than 10 mL/min must receive a dose every 24 hours. The 875 mg/125 mg tablet strength is not recommended for use in patients with severe renal impairment (CrCl < 30 mL/min).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Unimoc

Evidence for Use in Respiratory and Ear Infections

The research on Unimoc for common respiratory and ear infections is largely drawn from Randomized Controlled Trials (RCTs) and Systematic Reviews that included comparisons to other treatment regimens or observation. Researchers examined whether the use of Unimoc was associated with outcomes related to physical discomfort and systemic or functional imbalance. For conditions like acute bacterial rhinosinusitis and acute otitis media, trials observed measurements of clinical success and documented microbiological findings related to specific bacteria in children and adults.

Studies for community-acquired pneumonia (CAP) monitored patient outcomes such as the rate of symptom change or clinical status and, in some cases, the rate of hospitalization. Findings describe patterns observed in these studies, but evidence consistency across all pneumonia subtypes is a focus of ongoing research. Data from some trials describe research exploring outcomes for certain respiratory infections caused by organisms that resist amoxicillin alone.

Evidence for Use in Skin and Soft Tissue Infections

The evidence base for Unimoc's use in skin and soft tissue infections (SSTIs) like cellulitis includes RCTs that included comparison regimens and Observational Studies. Research primarily focused on measured outcomes related to change in clinical status and evolution of localized signs such as swelling and pain, especially in conditions associated with acute or disruptive episodes like animal or human bites. The trials explored short-term symptom changes over a defined time interval, usually the course of treatment. Findings describe patterns observed in the studies related to microbiological reduction patterns for certain bacteria that produce resistance mechanisms. Evidence quality varies across studies, with some focusing on specific infection types like traumatic wounds.

What is Still Uncertain About Unimoc's Research Base

The research provides insight into short-term changes, but several limitations in the overall evidence landscape persist. Limited information exists regarding long-term outcomes, such as tracking the risk of recurrence over many months, as follow-up durations were limited in many primary RCTs. Furthermore, data for certain groups remain insufficient (e.g., infants younger than three months or patients with severe comorbidities). Comparative evidence is lacking in some scenarios against newer antibiotic classes. Research is ongoing to address the implications of increasing bacterial resistance and to better contextualize the evidence landscape for this agent.

Key Studies & References

  1. Treatment of skin and soft tissue infections by amoxicillin/clavulanic acid: a review of the clinical and microbiological efficacy

Frequently Asked Questions (FAQ)

Common questions about Unimoc (FAQ)

Q: Does Unimoc have a different active ingredient than older similar medicines?

A: Unimoc is a combination medicine containing two active components: Amoxicillin, which is a penicillin-class antibiotic, and Clavulanate Potassium. The addition of Clavulanate Potassium is what distinguishes it from older antibiotics containing Amoxicillin alone. According to official documents, this second ingredient helps the medicine remain effective against certain resistant bacteria.

Q: Is it okay to take Unimoc every day?

A: Regulatory instructions describe that the medicine is generally taken on a daily basis for the duration of the prescribed course. Official documents state that this course of treatment should typically not exceed 14 days without re-evaluation.

Q: How quickly should I expect Unimoc to start working?

A: Official product information describes that the active components are rapidly absorbed into the bloodstream after being taken orally. The highest levels of the medicine in the blood are usually reached about 1 to 2 hours after a dose. This information describes how quickly the active components are found in the bloodstream.

Q: What happens if I miss a time I was supposed to take Unimoc?

A: Official patient guidance describes general principles for managing missed doses: taking the dose upon remembering, unless it is close to the next scheduled time. The guidance specifies that a double dose is not advised to make up for the one that was missed.

Q: Are there any common over-the-counter medicines that interact with Unimoc?

A: The official documentation lists specific prescription drugs, such as certain blood thinners and medicines for gout or cancer, that interact with Unimoc. However, commonly used, non-prescription, over-the-counter medicines are generally not specifically detailed in the section of medically significant interactions.

Q: Does Unimoc affect my ability to drive or operate machinery?

A: Official regulatory documents list side effects like dizziness and headache as uncommon. Official sources describe that the presence of these side effects may be considered when performing tasks such as driving or operating machinery.

Q: Is it true that Unimoc can cause changes in mood?

A: Some psychiatric effects are described in regulatory documents, although their frequency is noted as uncommon or rare. These can include effects such as anxiety, hyperactivity, confusion, and insomnia.

Q: Can Unimoc affect my sleep?

A: Official documentation mentions insomnia (difficulty sleeping) as a possible side effect of Unimoc. This is typically listed among the uncommon or rare adverse reactions reported in regulatory sources.

Q: Can I take ibuprofen or acetaminophen while using Unimoc?

A: Regulatory interaction lists are focused on specific prescription drugs (e.g., anticoagulants and methotrexate) and generally do not include common non-prescription pain relievers like ibuprofen or acetaminophen in the section of medically significant interactions.

Q: What is the difference between Unimoc and a generic version of the same type of medicine?

A: Unimoc is a brand name for the pharmaceutical combination known as Amoxicillin and Clavulanate Potassium. Generic versions contain the identical active ingredients, in the same strength and dosage form. Regulatory agencies affirm that generic products are considered therapeutically equivalent to the brand-name product.

Q: Can I stop using Unimoc as soon as I feel better?

A: Official guidance emphasizes that the full prescribed course of treatment is intended to be completed, even if symptoms begin to improve early. Discontinuing treatment early or skipping doses is noted to increase the risk of developing drug-resistant bacteria.

Q: Can using Unimoc make me feel more tired than usual?

A: General tiredness or fatigue is not listed among the most common adverse effects. However, official warnings for potentially serious liver events list unusual tiredness or weakness as possible signs that patients should be aware of.

Q: Why is Unimoc often mentioned alongside a specific dietary consideration?

A: The official product labeling gives the instruction to take the medicine at the start of a meal. This timing is specifically instructed to help enhance the absorption of the clavulanate component and to aid in minimizing the potential for gastrointestinal intolerance.

Q: What are people referring to when they say Unimoc is a 'new generation' medicine?

A: The medicine combines the antibiotic amoxicillin with clavulanic acid, a beta-lactamase inhibitor. This combination is described in official sources as enabling effectiveness against bacterial strains that have developed resistance to amoxicillin alone, distinguishing it from older, single-ingredient penicillins.

Q: How long does Unimoc stay in my system after the last use?

A: The half-life (T1/2) of the amoxicillin component is approximately 1.3 hours and the clavulanate component is about 1.0 hour. The half-life describes the time required for the amount of drug in the body to be reduced by half. This information is included in the official pharmacokinetic data.

Q: Is Unimoc classified as a controlled substance?

A: Official drug classification information indicates that Unimoc (Amoxicillin and Clavulanate Potassium) is not scheduled or classified as a controlled substance under the regulatory acts governing pharmaceuticals.

Q: Are there specific food items that I should avoid while using Unimoc (other than meal timing)?

A: While the requirement to take the medicine with a meal is common, the official labeling for some extended-release forms of the medicine specifically advises that it should not be taken with a high-fat meal. This is because high-fat content may decrease the absorption of the clavulanate component.

Q: How do I know if the side effects I'm having are serious?

A: Official regulatory documentation lists specific signs related to potentially serious reactions that warrant attention. These signs can include severe rash, yellowing of the skin or eyes (jaundice), dark urine, or severe or bloody diarrhea.

Q: Has Unimoc been studied in children?

A: The safety and effectiveness of the medicine have been officially established in pediatric patients. Clinical trials and pharmacokinetic studies, including those for common conditions like acute otitis media, have been conducted in children.

Q: Do people with asthma or allergies (general) have to be careful with Unimoc?

A: Official warnings note that serious hypersensitivity reactions are more likely to occur in individuals who have a history of penicillin allergy. The warnings also include a caution for those with a history of sensitivity to multiple allergens.

Q: What happens if I accidentally take more Unimoc than prescribed?

A: The overdosage section in official documents reports that observed effects have sometimes included stomach pain, vomiting, diarrhea, rash, hyperactivity, or drowsiness. Treatment in these situations is generally managed by supportive care measures.

Q: Is Unimoc used to treat any conditions other than its main approved uses?

A: Regulatory documents list the specific conditions for which the product is approved (e.g., infections of the ear, skin, respiratory tract). Official instructions restrict use to infections proven or strongly suspected to be caused by susceptible bacteria.

Q: If I have a history of seizures, can I still use Unimoc?

A: Official documentation reports that convulsions (seizures) are an uncommon adverse reaction. This reaction may occur in patients with impaired kidney function or in those who receive high doses of the medicine.

Q: Can I save leftover Unimoc for a future need?

A: Regulatory guidance describes that any unused or expired medicine is intended to be disposed of. This is done via official drug take-back programs or by following documented household trash disposal instructions.

Q: What is the role of Unimoc in a full course of treatment?

A: Unimoc is indicated to be used as a treatment for bacterial infections that are proven or strongly suspected to be caused by specific susceptible bacteria. It is intended to be used for a defined duration of therapy, known as a full course of treatment.

Q: Is it normal for a doctor to recommend blood tests before using Unimoc?

A: Official documents advise that for patients with existing liver or kidney impairment, monitoring liver function and making dose adjustments is necessary. This suggests that blood tests may be relevant for evaluating patients with specific health conditions.

Q: Does the time of day matter when taking Unimoc?

A: The official instruction is to take the medicine on a consistent schedule, such as every 12 hours or every 8 hours, and to take the dose at the start of a meal. The label does not mandate a specific time of day (e.g., morning or evening) but stresses consistent intervals and timing relative to food.

How should Unimoc be stored and disposed of?

How to Store and Dispose of Unimoc

Official regulatory documents require that Unimoc be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions to 15 C to 30 C (59 F and 86 F). The medicine must be kept in its original, tightly closed, child-resistant container to ensure physical security and protect it from moisture and freezing temperatures.

Secure storage is essential; keep Unimoc out of the sight and reach of children at all times. Disposal of unused or expired Unimoc should follow official guidelines, which typically involve utilizing an authorized drug take-back program. If no take-back program is available, follow documented instructions for proper household trash disposal, and do not flush the medicine down the toilet unless explicitly specified by the product labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unimoc found in:

A-Z Index: